With more than 400 development programs under our belt, Pii’s highly trained scientific team has extensive experience working with a variety of drug substances having a range of physiochemical characteristics. Additionally, Pii’s development capabilities include modified and extended release formulations. For poorly soluble compounds, Pii offers a variety of Bioavailability enhancement technologies, including solid dispersion development and lipid based or micro/nano emulsions.
An estimated 40% of the drugs in the development pipeline are considered poorly soluble. Pii’s highly trained scientific team has extensive experience working with a variety of drug substances having a range of physiochemical characteristics. For poorly soluble compounds, Pii offers multiple bioavailability enhancement technologies. Designing efficient drug delivery systems for poorly soluble drugs is not a one size fits all approach. When selecting the right solubilisation technology, a number of important factors need to be considered. To be successful, it is important to carefully tailor the development process to the specific characteristics of the API. From solid dispersions to lipid carriers, Pii has the right tools and breadth of experience to meet your compounds specific needs.